Below is a listing of active clinical trials currently running at Carolinas HealthCare System NorthEast, a facility of Carolinas HealthCare System NorthEast. For more information about any of the trials you see on this page, please contact one of our clinical research nurses at 704-403-1520.

Breast Cancer
B-43 A clinical trial comparing Trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-Positive
B-47 A randomized Phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of Docetaxel plus Cyclophosphamide or four cycles)
B-49 A Phase III clinical trial comparing the combination of Docetaxel plus Cyclophosphamide to Anthracycline-based chemotherapy regimens for women with Node-Positive or High-Risk Node-Negative, HER2-Negative breast cancer
E2108 A randomized Phase III trial of the value of early local therapy for the intact primary tumor in patients with metastatic breast cancer
1025 A Phase II study evaluating the efficacy and tolerability of Everolimus (RAD001) in combination with Trastuzumab and Vinorelbine in the treatment


Lung Cancer
E1505 A Phase III randomized trial of adjuvant chemotherapy with or without Bevacizumab for patients with completely resected Stage IB - IIIA Non-Small Cell Lung Cancer (NSCLC)


Brain Cancer
E3F05 Phase III study of radiation therapy with or without Temozolomide for Symptomatic or Progressive Low Grade Gliomas


Kidney & Pancreas
ECOG 2805 Oral chemotherapy (Sutent vs. Nexavar vs. Placebo) for resected kidney cancer
CP02-0555 Frontline targeted therapy with or without chemotherapy for metastatic pancreatic cancer


CALGB 80405 Chemotherapy + targeted therapy for front-line treatment of metastatic colon cancer
ECOG 5202 Chemotherapy + targeted therapy for Stage II colon cancer that has a high risk of recurrence


04-22  A Phase II/III, multicenter, randomized, controlled study to compare the efficacy and safety of Gemcitabine alone vs. ON 01910. Na Combined
0848 A Phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma
Z5041 A Phase II Study of Preoperative Gemcitabine and Erlotinib plus pancreatectomy and postoperative Gemcitabine and Erlotinib for patients with operable pancreatic adenocarcinoma
1010 A phase III trial evaluating the addition of Trastuzumab to Trimodality treatment of Her2-Overexpressing esophageal adenocarcinoma
80702 A Phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus Celecoxib or Placebo for patients with resected Stage III colon cancer
STX0206 Randomized comparative study of FOLFOX6m plus SIR-SPHERES Microspheres vs FOLFOX6m alone as first line treatment in patients with nonresectable liver mets from primary colorectal carcinoma


90601 A randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and placebo in patients with advanced transitional cell carcinoma
S0931 EVErolimus for renal cell ensuing surgical therapy, a Phase III study


274 A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL
277 A Phase III randomized trial of Gemcitabine plus Docetaxel followed by Doxorubicin (NSC# 123127) v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma
229K A Phase II evaluation of BIBF 1120 (IND#113086) in the treatment of recurrent or persistent endometrial carcinoma.
273 Chemotherapy toxicity in elderly women with ovarian, primary peritoneal, or fallopian tube cancer
267 Quality of life and care needs in patients with persistent or recurrent platinum-resistant ovarian, fallopian tube, and peritoneal cancer


Head & Neck
1016 Phase III trial of radiotherapy plus Cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer


VALOR Sunesis:  A Phase 3, randomized, controlled, double-blind, multinational clinical study of the efficacy and safety of Vosaroxin and Cytarabine versus placebo and Cytarabine in patients with first relapsed or refractory acute myeloid leukemia (VALOR)


NSABP R-04 Chemotherapy & Radiation Therapy before surgery for operable rectal cancer
ECOG 5204 Chemotherapy + Targeted Therapy (Avastin) after chemotherapy and radiation therapy followed by rectal surgery


20070782 Randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alfa administered at 500 mcg once-every-3-Weeks in anemic subjects with advanced stage non-small cell lung cancer receiving multi-cycle chemotherapy
S1013 A prospective study of epidermal growth factor receptor (HER-1/EGFR) inhibitor-induced dermatologic toxicity: Validation of the functional assessment of cancer therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities


1011 A Phase II trial of Bendamustine in combination with Rituximab in older patients with previously untreated diffuse large B-cell lymphoma
50604 A Phase II trial of response-adapted chemotherapy based on Positron Emission Tomography (PET) for non-bulky Stage I and II Hodgkin Lymphoma
50801 A Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
N2301 A randomized, double-blind, placebo-controlled, multi-center Phase III Study of RAD001 adjuvant therapy in poor risk patients with diffuse large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line Rituximab-chemotherapy
OFB114612 Phase II open-label study of Ofatumumab and Bendamustine followed by maintenance Ofatumumab for indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) which has relapsed after Rituximab Therapy or a Rituximab-Containing Therapy
COMPLETE Prospective, longitudinal, multinational registry of patients with newly diagnosed peripheral T-Cell Lymphoma